Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
DAWN Day One Biopharmaceuticals
21.110-0.640-2.94%
Close
02/03 16:00 ET
21.150+0.040+0.19%
Post Mkt Price 02/03 19:32 ET
High
21.975
Open
21.300
Turnover
9.26M
Low
20.920
Pre Close
21.750
Volume
434.25K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Where Day One Biopharmaceutical Stands With Analysts
Within the last quarter, Day One Biopharmaceutical (NASDAQ:DAWN) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings61000Last 30D000001M
Day One Biopharm Initiated at Perform by Oppenheimer
Day One Biopharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/03/2023 — Oppenheimer Initiates Coverage On → Perform 01/09/2023 185.06% Goldman Sachs $45 → $62 Maint
Oppenheimer Initiates Coverage On Day One Biopharmaceutical With Perform Rating
Oppenheimer analyst Matthew Biegler initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Perform rating.
Oppenheimer Begins Coverage on Day One Biopharmaceuticals (NASDAQ:DAWN)
Analysts at Oppenheimer started coverage on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The brok
Day One Biopharmaceuticals Initiated With a Perform at Oppenheimer
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 25.1% in January
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 5,590,000 shares, a g
Insider Sell: Day One Biopharmaceuticals
05:17 PM EST, 01/24/2023 (MT Newswires) -- Jeremy Bender, Director, Chief Executive Officer, on January 23, 2023, sold 12,500 shares in Day One Biopharmaceuticals (DAWN) for $274,988. Following the Fo
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 Shares
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, January 10th.
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $45.00
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) had its price objective raised by HC Wainwright from $35.00 to $45.00 in a research report sent to investors on Monday morning, The Fly reports.
Company Overview
More
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.
CEO： Dr. Jeremy Bender
Market： NASDAQ
Listing Date： 05/27/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet